Dealing by Directors

Companies Act 1985 Sections 324/329 Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R

We hereby inform you that on 24 February 2006, the following Directors acquired an interest in the USD0.25 Ordinary Shares of AstraZeneca PLC. The interest arises as a result of the previously disclosed arrangements relating to the payment of annual bonuses for 2005 whereby each individual is required to defer a portion of the bonus earned into shares for a period of three years. The shares were allocated at a price of 2639 pence per share. The individuals will become beneficially entitled to these shares on 24 February 2009. Number of shares Total interest in Percentage of shares in Name allocated shares after this issue allocation J R Symonds 7,534 66,784 0.004% J S Patterson 6,623 49,071 0.003% G H R Musker Company Secretary 28 February 2006 AstraZeneca AB SE-151 85 Södertälje Sweden Tel +46 8 553 260 00 Fax+46 8 553 290 00

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links